Results 91 to 100 of about 18,617,874 (263)

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges

open access: yesAdvanced Science, EarlyView.
Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib   +8 more
wiley   +1 more source

Open-Label Placebos as Adjunct for the Preventive Treatment of Migraine

open access: yesJAMA Network Open
Importance Placebo effects contribute substantially to the therapeutic success of many treatments, particularly in pain-related conditions. Open-label placebos (OLPs) offer an ethically acceptable approach to harness this potential without deception ...
Kleine-Borgmann, Julian   +6 more
openaire   +5 more sources

Safety Profile of Opicapone in the Management of Parkinson’s Disease

open access: yesJournal of Parkinson’s Disease, 2019
Background: Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson’s disease (PD) and motor fluctuations.
Andrew Lees   +6 more
doaj   +1 more source

Changes of allergic symptoms for open-label placebo and control group for single symptom groups (mean and standard error).

open access: yes, 2018
Results show significant improvements for the open-label placebo group but not for the control group. * p < 0.05, (*) p = 0.06.
Benjamin Berstecher (4919128)   +2 more
core   +1 more source

OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD

open access: yesAdvanced Science, EarlyView.
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li   +11 more
wiley   +1 more source

The role of the motor component in an open-label placebo intervention to reduce emotional discomfort when viewing negative images

open access: yes, 2023
Die vorliegende Studie untersuchte die Auswirkung der motorischen Komponente bei einer Open-Label-Placebo Intervention zur Reduktion des Unbehagens (Valenz) und der subjektiven Erregung (Arousal) sowie kardiovaskulärer Parameter, beim Betrachten ...
Keßler, Jarmila Magdalena
core  

Open-label placebos, rituals, and well-being

open access: yes, 2021
The experiment aims are to test: a) whether open-label placebo (OLP) capsules can improve self-reported measures of wellbeing in a healthy population, and b) whether adding ritualistic components to the OLP capsules use can further enhance the OLP effect.
Marco Valerio
core   +1 more source

Enteric ChAT‐Expressing Neurons Mediate the Protective Effect of Lactobacillus plantarum in Inflammatory Bowel Disease

open access: yesAdvanced Science, EarlyView.
In colitis patients and mice, reduced Lactobacillus abundance is observed. Experimental studies show that L. plantarum A736 metabolizes dietary tryptophan into indole‐3‐lactic acid (ILA), while both L. plantarum A736 and ILA impact ChAT‐expressing enteric neurons and acetylcholine levels, thereby regulating intestinal immune responses and alleviating ...
Bing Xia   +15 more
wiley   +1 more source

The therapeutic oxymoron: exploring the mechanisms of open-label placebo

open access: yes, 2023
Placebos have emancipated themselves from earlier, often unethical or merely research- based practices, toward an open and thereby ethical administration. Despite a plethora of efficacy studies and nearly two decades of empirical research on open-label placebos (OLPs), little to nothing is known about the circumstances under which they realize their ...
openaire   +1 more source

Home - About - Disclaimer - Privacy